Medicare to Offer Lower Prices on 15 Popular Medications for Chronic Illnesses: Full List and Details
In a significant move aimed at reducing prescription drug costs for millions of Americans, the federal government has announced a deal to substantially lower prices on 15 widely used medications covered by Medicare. This initiative promises major savings for the Medicare program and is expected to ease the financial burden on beneficiaries managing chronic diseases.
Background and Impact
The new pricing agreements, announced in late 2025, stem from the Inflation Reduction Act passed in 2022. This landmark legislation granted Medicare, for the first time, the authority to negotiate drug prices directly with pharmaceutical companies, a power previously banned by law. Through these negotiations, the government aims to leverage Medicare’s considerable buying power to secure lower prices.
According to official projections, Medicare’s spending on these 15 drugs will be reduced by approximately 44%, translating to an estimated $12 billion in savings for the program. The negotiated discounts range widely, with price cuts between 38% and 85% off current list prices that patients and the program have been paying.
Who Benefits and How Much?
The savings will impact the roughly 5.3 million Medicare Part D enrollees who use at least one of the discounted medications. While Medicare covers about 55 million people through its Part D prescription drug plan, not all beneficiaries will experience these reduced drug costs.
On average, the new pricing deals are expected to save these users around $129 each per year in out-of-pocket costs. However, this figure varies considerably depending on the specific drugs taken and how close individuals come to Medicare’s annual spending limits.
Notably, Medicare beneficiaries already benefit from an annual cap on out-of-pocket prescription drug expenses, set to $2,000 beginning in 2025 and projected to rise gradually with inflation. After patients reach this cap, they do not pay further drug costs, meaning savings beyond that threshold primarily help Medicare’s finances rather than individual users.
Medications Included in the Deal
The list includes several high-profile and widely used medications, especially those treating chronic conditions such as diabetes, asthma, and prostate cancer. Of special note are Novo Nordisk’s Ozempic and Wegovy, drugs that have witnessed a surge in demand due to their effectiveness in treating type 2 diabetes and aiding weight loss.
Overall, these medications account for over $40 billion in annual Medicare Part D spending, making the negotiated discounts a major financial relief for the program.
The Bigger Picture
Prescription drug affordability remains a top concern for seniors, according to surveys from AARP and other advocacy groups. Merith Basey, executive director of Patients For Affordable Drugs, emphasized that Medicare’s newfound ability to negotiate prices is “the most powerful tool we currently have” to hold pharmaceutical companies accountable and rein in rising drug costs.
Furthermore, the programwide savings help fund the essential out-of-pocket spending cap, providing extra financial protections for Medicare recipients.
Complexities Around GLP-1 Drugs Pricing
However, the situation is nuanced by separate, recent drug pricing agreements negotiated by the Trump administration in November 2025. These include arrangements that lower the monthly costs of GLP-1 drugs — a class that encompasses Wegovy, Ozempic, and the newer Zepbound — for Medicare and Medicaid beneficiaries, as well as users of the upcoming TrumpRX platform.
Under these agreements, Medicare patients would pay approximately $245 monthly for such drugs, which is lower than the $274 per month price CMS negotiated for 2027. This overlap highlights the evolving landscape of drug pricing policies impacting Medicare enrollees.
Implementation Timeline
The new negotiated prices will officially take effect in 2027 for medications purchased through Medicare Part D plans, giving beneficiaries and providers time to prepare for the changes.
Summary of Key Points:
- Medicare has negotiated lower prices on 15 popular medications treating chronic illnesses.
- Expected Medicare savings are about 44%, or $12 billion annually.
- Around 5.3 million Medicare beneficiaries who use these drugs could save an average of $129 each per year.
- Discounts range from 38% to 85% off current drug prices.
- Medications include Ozempic, Wegovy, and drugs for asthma, prostate cancer, and other conditions.
- Out-of-pocket spending caps also protect Medicare users, limiting patient expenses.
- New prices are effective starting in 2027 under Medicare Part D.
- Separate Trump administration agreements offer additional price cuts on some GLP-1 drugs.
This development marks a significant step toward addressing the long-standing issue of high prescription drug costs in the United States, providing some financial relief for seniors and aiding the sustainability of the Medicare program. For more detailed information and the full list of drugs included, beneficiaries are encouraged to visit the official Medicare website or consult with their healthcare providers.
Source: Marca, Centers for Medicare & Medicaid Services (CMS)